• Like

Amyotrophic Lateral Sclerosis (ALS) - Opportunity Analysis and Forecasts to 2018

  • 128 views
Uploaded on

Market Research Reports, Inc. has announced the addition of “OpportunityAnalyzer: Amyotrophic Lateral Sclerosis (ALS) - Opportunity Analysis and Forecasts to 2018” research report to their offering. …

Market Research Reports, Inc. has announced the addition of “OpportunityAnalyzer: Amyotrophic Lateral Sclerosis (ALS) - Opportunity Analysis and Forecasts to 2018” research report to their offering. See more at- http://mrr.cm/ZP3

  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Be the first to comment
    Be the first to like this
No Downloads

Views

Total Views
128
On Slideshare
0
From Embeds
0
Number of Embeds
1

Actions

Shares
Downloads
0
Comments
0
Likes
0

Embeds 0

No embeds

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
    No notes for slide

Transcript

  • 1. www.MarketResearchReports.com Category : Pharma & Healthcare All logos and Images mentioned on this slide belong to their respective owners.
  • 2. www.MarketResearchReports.com Introduction to Report  Launch Date: June 20, 2014  Number of Pages: 134  Geography Coverage: Global  Available Format: PDF Price For Single User License: USD 5,995 Price For Site License: USD 11,990 Price For Global User License: USD 17,985 Delivery Time: Within 24 Hours (During Working Days)
  • 3. www.MarketResearchReports.com About the Report Amyotrophic lateral sclerosis (ALS) is a rare, but fatal, motor neuron disease (MND) characterized by axonal degeneration and progressive loss of motor neurons. ALS affects both the upper (brain to spinal cord) and lower (brain stem to muscle tissue) motor neurons, gradually reducing a patient’s ability to initiate and control muscle movement. Muscle atrophy, starting in the periphery (arms and legs), ultimately leads to complete paralysis after several years of progressive worsening of muscle strength. Respiratory failure is the most common cause of death, as smooth muscle function becomes affected when the disease is in its final stages. The progressively degenerative course of the condition is a great burden for both patients and caregivers, as well as for society. ALS usually affects people age =40 years, and has a worldwide incidence of about two cases per 100,000 population, and a prevalence ranging between four and seven cases per 100,000.
  • 4. www.MarketResearchReports.com Research Findings Patent Expiration of Rilutek to Cause Negative Growth in Amyotrophic Lateral Sclerosis Treatment Market by 2018 The amyotrophic lateral sclerosis (ALS) treatment market value will decline from $64 million in 2013 to $38 million by 2018, at a negative Compound Annual Growth Rate (CAGR) of 10.05%, according to research and consulting firm by Publisher. The company’s latest report states that the largest factor in this decline, which will occur over seven major markets (7MM: the US, France, Germany, Italy, Spain, the UK, and Japan), will be the patent expiration of Rilutek (riluzole), the only approved therapy for ALS. As a consequence, Publisher forecasts that the ALS treatment market in the US is set to suffer a substantial reduction in sales over the forecast period, from $38 million in 2013 to $16 million by 2020, at a negative CAGR of 16.10%.
  • 5. www.MarketResearchReports.com Scope Overview of ALS, including etiology and pathophysiology, general symptoms, quality of life, country-specific treatment recommendations and epidemiologic data. Annualized ALS market revenue, annual cost of treatment and usage patterns from 2013 and forecast for five years to 2018. Key topics covered include unmet needs analysis, research and development strategies, pipeline assessment, and pipeline valuation analysis for the ALS market. Pipeline valuation analysis: clinical and commercial benchmarking of AB Science’s AB-1010 (masitinib), Cytokinetics’ CK-2017357 (tirasemtiv), Mitsubishi Tanabe’s Radicut (edaravone), Eisai’s Methycobal (mecobalamin), and Orphazyme ApS’ arimoclomol. Assessment of the current and future market competition in the global ALS drug market. Insightful review of the key industry and governmental drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
  • 6. www.MarketResearchReports.com Report Coverage 1. Table of Contents 2. Introduction 3. Disease Overview 4. Epidemiology 5. Current Treatment Options 6. Unmet Needs Assessment and Opportunity Analysis 7. Research and Development Strategies 8. Pipeline Assessment 9. Pipeline Valuation Analysis 10.Appendix For more details regarding Report coverage see the last slide All logos and Images mentioned on this slide belong to their respective owners.
  • 7. www.MarketResearchReports.com Custom Research:  Are you an industry professional, entrepreneur, venture capitalist, investors and organization, then let us know your specific research requirements. Our goal is to cater to your requirements be it for a custom market research project, syndicated research report on a specific market or industry sector, newsletter creation, case study development or anything else related to marketing research. For Any Customization Related query Visit IdeaCenter @ http://www.marketresearchreports.com/idea-center
  • 8. www.MarketResearchReports.com How To Buy This Report? Visit following URL to see Table of Content and purchase this publication: http://mrr.cm/ZP3 About Market Research Reports, Inc. Market Research Reports provides a customized set of reports from reputed Publishers, built on the intelligence available within organizations and leverages on our motto of “Intelligence Redefined”. Contact : Amitava Sen Email : info@marketresearchreports.com Phone: +1 302-703-7787 (USA) +91-8762746600 (India)